These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1419619)

  • 81. Elevated liver function tests in a patient with breast cancer.
    Neftel C; Zaman K; Chtioui H; Moradpour D; Sempoux C; Fraga M
    J Hepatol; 2023 Sep; 79(3):e109-e111. PubMed ID: 37599061
    [No Abstract]   [Full Text] [Related]  

  • 82. THE CLEARANCE OF BILIRUBIN FROM THE PLASMA. A MEASURE OF THE EXCRETING POWER OF THE LIVER.
    Weech AA; Vann D; Grillo RA
    J Clin Invest; 1941 May; 20(3):323-32. PubMed ID: 16694839
    [No Abstract]   [Full Text] [Related]  

  • 83. Clinical implications of enzyme induction and enzyme inhibition.
    Park BK; Breckenridge AM
    Clin Pharmacokinet; 1981; 6(1):1-24. PubMed ID: 6113907
    [TBL] [Abstract][Full Text] [Related]  

  • 84. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Action mechanisms of cough suppressants and their clinical application].
    Płusa T
    Pol Merkur Lekarski; 2014 Jan; 36(211):48-53. PubMed ID: 24645580
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.
    Jain R; Grabner M; Onukwugha E
    Pharmacoeconomics; 2011 Apr; 29(4):297-314. PubMed ID: 21395350
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
    Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
    Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Positioning pharmacy for the 21st century.
    Doluisio JT
    DICP; 1989 Sep; 23(9):706-10. PubMed ID: 2800587
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence.
    Campbell JD; McQueen RB; Briggs A
    Ann Am Thorac Soc; 2014 Feb; 11 Suppl 2():S105-11. PubMed ID: 24559022
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Molecular mechanism of drug tolerance and dependence].
    Osugi T; Ikemoto M; Taniura H; Miki N
    Nihon Yakurigaku Zasshi; 1991 Sep; 98(3):187-95. PubMed ID: 1660443
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effect of Transarterial Chemotherapy on the Structure and Function of Gut Microbiota in New Zealand White Rabbits.
    Bai L; Yan X; Qi P; Lv J; Song X; Zhang L
    Biology (Basel); 2024 Mar; 13(4):. PubMed ID: 38666842
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Dose adaptation of antineoplastic drugs in patients with liver disease.
    Tchambaz L; Schlatter C; Jakob M; Krähenbühl A; Wolf P; Krähenbühl S
    Drug Saf; 2006; 29(6):509-22. PubMed ID: 16752933
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pharmacology of anticancer drugs in the elderly population.
    Wildiers H; Highley MS; de Bruijn EA; van Oosterom AT
    Clin Pharmacokinet; 2003; 42(14):1213-42. PubMed ID: 14606930
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
    Ormrod D; Holm K; Goa K; Spencer C
    Drugs Aging; 1999 Nov; 15(5):389-416. PubMed ID: 10600046
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 98. What is the effect of adjusting epirubicin doses for body surface area?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Sep; 78(5):662-6. PubMed ID: 9744507
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Apr; 77(7):1145-8. PubMed ID: 9569053
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.